EFG International AG Purchases Shares of 2,539 IQVIA Holdings Inc. $IQV

EFG International AG purchased a new stake in IQVIA Holdings Inc. (NYSE:IQV) during the second quarter, according to its most recent 13F filing with the SEC. The firm purchased 2,539 shares of the medical research company’s stock, valued at approximately $491,000.

Other large investors have also recently modified their holdings of the company. Redwood Grove Capital LLC purchased a new stake in IQVIA during the second quarter valued at approximately $18,066,000. Primecap Management Co. CA purchased a new position in IQVIA in the second quarter worth $7,142,000. Canada Pension Plan Investment Board acquired a new position in shares of IQVIA during the second quarter worth $240,911,000. Parkman Healthcare Partners LLC purchased a new stake in shares of IQVIA during the 2nd quarter valued at $20,445,000. Finally, Lakewood Capital Management LP purchased a new stake in shares of IQVIA during the 2nd quarter valued at $61,425,000. Institutional investors own 89.62% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently weighed in on IQV shares. Wall Street Zen upgraded IQVIA from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. BMO Capital Markets increased their price target on IQVIA from $210.00 to $270.00 and gave the company an “outperform” rating in a research note on Wednesday, July 29th. JPMorgan Chase & Co. raised their price target on IQVIA from $225.00 to $285.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Morgan Stanley restated an “equal weight” rating and set a $200.00 price target (down from $225.00) on shares of IQVIA in a research note on Wednesday, June 17th. Finally, TD Cowen increased their price objective on shares of IQVIA from $233.00 to $288.00 and gave the company a “buy” rating in a research report on Wednesday, July 29th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, IQVIA has an average rating of “Moderate Buy” and an average price target of $241.88.

Insider Buying and Selling at IQVIA

In related news, insider Eric Sherbet sold 5,000 shares of the business’s stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the completion of the transaction, the insider directly owned 20,999 shares in the company, valued at $5,232,110.84. The trade was a 19.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Keriann Cherofsky sold 558 shares of the company’s stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $245.21, for a total transaction of $136,827.18. Following the completion of the sale, the insider directly owned 2,989 shares in the company, valued at approximately $732,932.69. The trade was a 15.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 12,913 shares of company stock worth $3,098,793. 1.70% of the stock is currently owned by company insiders.

IQVIA Price Performance

NYSE IQV opened at $262.18 on Friday. The stock’s fifty day moving average price is $220.29 and its 200 day moving average price is $189.12. IQVIA Holdings Inc. has a 1 year low of $154.50 and a 1 year high of $265.25. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71. The company has a market cap of $43.15 billion, a price-to-earnings ratio of 32.53, a PEG ratio of 2.23 and a beta of 1.18.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. The company had revenue of $4.37 billion during the quarter, compared to analyst estimates of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. IQVIA’s revenue for the quarter was up 8.7% compared to the same quarter last year. During the same period last year, the firm posted $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, equities research analysts forecast that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

IQVIA announced that its board has approved a stock repurchase program on Thursday, May 7th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to purchase up to 6.8% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.